We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

donderdag 27 juli 2017

The Lancet: [Articles] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian ...

[Articles] Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation. Apart from anaemia, toxicities with olaparib were low grade and manageable.
Read more

[Comment] To promote maintenance or treatment, is that the question?
Poly(ADP-ribose) polymerase (PARP) inhibitors are emerging as a valuable class of agents in the management of ovarian cancer. They target DNA repair, particularly in tumours rendered deficient in homologous recombination through a germline or somatic BRCA1 or BRCA2 (BRCA1/2) mutation. The phase 3, double-blind, placebo-controlled SOLO2 trial reported in The Lancet Oncology by Eric Pujade-Lauraine and colleagues1 reinforces important data from multiple studies with olaparib and similar agents in women with recurrent epithelial ovarian cancer.
Read more

[Comment] The true value of altered fractionation in head and neck cancer
Radiotherapy has a major role in the treatment of cancers of the head and neck. Substantial progress in improving the efficacy of radiotherapy has been made in the past few decades. Technological progress, with the introduction of intensity-modulated radiotherapy, allows high-dose radiation to be deposited at the tumour site while minimising the dose to the surrounding normal tissues, leading to reduced acute and late toxicity. Randomised trials, such as the PARSPORT-trial,1 have shown the benefit of intensity-modulated radiotherapy, reporting greater reductions in xerostomia with intensity-modulated radiotherapy compared with conventional radiotherapy techniques.
Read more

[Articles] Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis
This update confirms, with more patients and a longer follow-up than the first version of MARCH, that hyperfractionated radiotherapy is, along with concomitant chemoradiotherapy, a standard of care for the treatment of locally advanced head and neck squamous cell cancers. The comparison between hyperfractionated radiotherapy and concomitant chemoradiotherapy remains to be specifically tested.
Read more

[News] Concurrent chemotherapy and proton beam therapy in NSCLC
Proton beam radiotherapy with concurrent chemotherapy is safe and might be effective in patients with locally advanced inoperable non-small-cell lung cancer (NSCLC), according to new research.
Read more